This is a summary of the European public assessment report (EPAR) for Memantine Mylan. It explains how the Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Memantine Mylan. For practical information about using Memantine Mylan, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Treatment of patients with moderate to severe Alzheimer’s disease.
Therapeutic Area (MeSH)
ATC Code
N06DX01
ATC Item
memantine
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| memantine hydrochloride | N/A | 美金刚 |
EMA Name
Memantine Mylan
Medicine Name
Memantine Mylan
Aliases
N/ANo risk management plan link.
